These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28848040)

  • 21. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
    Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
    Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zirconium-containing nanoscale coordination polymers for positron emission tomography and fluorescence-guided cargo delivery to triple-negative breast tumors.
    Li YP; Pan ZW; Jiang YJ; Peng YY; Cai T; Hong H; Wang XF
    Acta Biomater; 2024 Apr; 179():313-324. PubMed ID: 38490483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GNA13 suppresses proliferation of ER+ breast cancer cells via ERα dependent upregulation of the MYC oncogene.
    Subramanyan LV; Rasheed SAK; Wang L; Ghosh S; Ong MSN; Lakshmanan M; Wang M; Casey PJ
    Breast Cancer Res; 2024 Jul; 26(1):113. PubMed ID: 38965558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation.
    Shu L; Chen A; Li L; Yao L; He Y; Xu J; Gu W; Li Q; Wang K; Zhang T; Liu G
    Oncogene; 2022 Feb; 41(6):907-919. PubMed ID: 34992218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.
    Palaskas N; Larson SM; Schultz N; Komisopoulou E; Wong J; Rohle D; Campos C; Yannuzzi N; Osborne JR; Linkov I; Kastenhuber ER; Taschereau R; Plaisier SB; Tran C; Heguy A; Wu H; Sander C; Phelps ME; Brennan C; Port E; Huse JT; Graeber TG; Mellinghoff IK
    Cancer Res; 2011 Aug; 71(15):5164-74. PubMed ID: 21646475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death-Dependent Changes in Glycolysis.
    Hesketh RL; Wang J; Wright AJ; Lewis DY; Denton AE; Grenfell R; Miller JL; Bielik R; Gehrung M; Fala M; Ros S; Xie B; Hu DE; Brindle KM
    Cancer Res; 2019 Jul; 79(14):3557-3569. PubMed ID: 31088837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[
    Capozza M; Anemone A; Dhakan C; Della Peruta M; Bracesco M; Zullino S; Villano D; Terreno E; Longo DL; Aime S
    Mol Imaging Biol; 2022 Feb; 24(1):126-134. PubMed ID: 34383241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
    Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
    Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
    [No Abstract]   [Full Text] [Related]  

  • 30. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment
    Gong C; Ma G; Hu X; Zhang Y; Wang Z; Zhang J; Zhao Y; Li Y; Xie Y; Yang Z; Wang B
    Oncologist; 2018 Oct; 23(10):1144-1152. PubMed ID: 30082489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
    Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.
    Koo HR; Park JS; Kang KW; Han W; Park IA; Moon WK
    Eur Radiol; 2015 Nov; 25(11):3314-21. PubMed ID: 25903708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
    McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N
    Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
    Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
    Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.
    Fricke IB; De Souza R; Costa Ayub L; Francia G; Kerbel R; Jaffray DA; Zheng J
    PLoS One; 2018; 13(5):e0196892. PubMed ID: 29723251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.